This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 Apr 17;370(16):1552-3.

doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11.

Therapy for hepatitis C--the costs of success

Jay H Hoofnagle¹, Averell H Sherker

Affiliations

Affiliation

¹ From the Liver Diseases Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

PMID: 24725236
DOI: 10.1056/NEJMe1401508

Editorial

Therapy for hepatitis C--the costs of success

Jay H Hoofnagle et al. N Engl J Med. 2014.

. 2014 Apr 17;370(16):1552-3.

doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11.

Authors

Jay H Hoofnagle¹, Averell H Sherker

Affiliation

¹ From the Liver Diseases Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

PMID: 24725236
DOI: 10.1056/NEJMe1401508

No abstract available

PubMed Disclaimer

Comment on

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Afdhal N, et al. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725238 Clinical Trial.

Similar articles

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2. Med Lett Drugs Ther. 2014. PMID: 25372848 No abstract available.
Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
Graf Einsiedel H, Christiansen H, Wiegand J. Graf Einsiedel H, et al. Pediatr Infect Dis J. 2016 Dec;35(12):1373. doi: 10.1097/INF.0000000000001336. Pediatr Infect Dis J. 2016. PMID: 27832030 No abstract available.
Hepatitis C and HIV co-infection: closing the gaps.
Graham CS. Graham CS. JAMA. 2015 Mar 24-31;313(12):1217-8. doi: 10.1001/jama.2015.1111. JAMA. 2015. PMID: 25705993 No abstract available.
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
German P, Mathias A, Brainard D, Kearney BP. German P, et al. Clin Pharmacokinet. 2016 Nov;55(11):1337-1351. doi: 10.1007/s40262-016-0397-0. Clin Pharmacokinet. 2016. PMID: 27193156 Review.
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Peter J, Nelson DR. Peter J, et al. Liver Int. 2015 Jan;35 Suppl 1:65-70. doi: 10.1111/liv.12718. Liver Int. 2015. PMID: 25529089 Review.

See all similar articles

Cited by

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C.
O'Brien TR, Witt DJ, Saxena V, Morrissey KG, Chen S, Baker FS, Prokunina-Olsson L, Pfeiffer RM, Lai JB. O'Brien TR, et al. J Infect. 2024 Nov;89(5):106258. doi: 10.1016/j.jinf.2024.106258. Epub 2024 Aug 30. J Infect. 2024. PMID: 39216831
Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.
Abdelaziz AI, Abdelsameea E, Abdel-Samiee M, Ghanem SE, Wahdan SA, Elsherbiny DA, Zakaria Z, Azab SS. Abdelaziz AI, et al. Clin Exp Med. 2024 Aug 8;24(1):184. doi: 10.1007/s10238-024-01432-x. Clin Exp Med. 2024. PMID: 39117877 Free PMC article.
Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States.
Yee LM, Shah SK, Grobman WA, Labellarte PZ, Barrera L, Jhaveri R. Yee LM, et al. PLoS One. 2022 Nov 18;17(11):e0277987. doi: 10.1371/journal.pone.0277987. eCollection 2022. PLoS One. 2022. PMID: 36399489 Free PMC article.
Predictive validity in drug discovery: what it is, why it matters and how to improve it.
Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, Richards D, Treherne JM. Scannell JW, et al. Nat Rev Drug Discov. 2022 Dec;21(12):915-931. doi: 10.1038/s41573-022-00552-x. Epub 2022 Oct 4. Nat Rev Drug Discov. 2022. PMID: 36195754 Review.
Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial.
Eckhardt B, Kapadia SN, Mateu-Gelabert P, Pai M, Fong C, Aponte-Melendez Y, Marks KM. Eckhardt B, et al. Open Forum Infect Dis. 2022 May 7;9(7):ofac225. doi: 10.1093/ofid/ofac225. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35821731 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- H1 Connect
- scite Smart Citations